MAQS legal advisor to Oblique Therapeutics in connection with rights issue

MAQS legal advisor to Oblique Therapeutics in connection with rights issue

MAQS has acted as legal advisor to Oblique Therapeutics AB (publ) in connection with a rights issue of approximately SEK 53.2 million.

Oblique Therapeutics is a privately held Swedish biotech company developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain and advanced cancer. For further information about the rights issue and Oblique Therapeutics, please refer to the company´s website.

Redeye and Eminova Partners acted as financial advisors to Oblique Therapeutics in connection with the rights issue.

MAQS´s team consisted mainly of Dag Fredlund, Anders Eriksson and Fredrik Brusberg.